These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23359319)

  • 1. Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.
    Jin G; Zheng SL; Lilja H; Kim ST; Tao S; Gao Z; Young T; Wiklund F; Feng J; Isaacs WB; Rittmaster RS; Gronberg H; Condreay LD; Sun J; Xu J
    Neoplasia; 2013 Jan; 15(1):95-101. PubMed ID: 23359319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
    Sävblom C; Halldén C; Cronin AM; Säll T; Savage C; Vertosick EA; Klein RJ; Giwercman A; Lilja H
    Clin Chem; 2014 Mar; 60(3):490-9. PubMed ID: 24270797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33.
    Parikh H; Deng Z; Yeager M; Boland J; Matthews C; Jia J; Collins I; White A; Burdett L; Hutchinson A; Qi L; Bacior JA; Lonsberry V; Rodesch MJ; Jeddeloh JA; Albert TJ; Halvensleben HA; Harkins TT; Ahn J; Berndt SI; Chatterjee N; Hoover R; Thomas G; Hunter DJ; Hayes RB; Chanock SJ; Amundadottir L
    Hum Genet; 2010 Jan; 127(1):91-9. PubMed ID: 19823874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
    Stimac G; Reljic A; Spajic B; Dimanovski J; Ruzic B; Ulamec M; Sonicki Z; Kraus O
    Scott Med J; 2009 Aug; 54(3):8-12. PubMed ID: 19725275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
    Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
    Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
    Sun J; Tao S; Gao Y; Peng T; Tan A; Zhang H; Yang X; Qin X; Hu Y; Feng J; Kim ST; Lin X; Wu Y; Zhang J; Li Z; Li L; Mo L; Liang Z; Shi D; Huang Z; Huang X; Liu M; Liu Q; Zhang S; Lilly Zheng S; Xu J; Mo Z
    Hum Genet; 2013 Apr; 132(4):423-9. PubMed ID: 23269536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
    Björk T; Lilja H; Christensson A
    BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN
    Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.